Original Article

Fiberoptic bronchoscopy for the prevention of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials

Haowei Tang¹, Zhi Yuan¹, Jingjie Li¹, Qun Wang¹, Weijie Fan¹

¹ Department of Respiratory Medicine, Fenghua District People's Hospital, Ningbo 315500, China

Abstract

Introduction: Ventilator-associated pneumonia (VAP) causes increased time of mechanical ventilation (MV), prolonged intensive care unit (ICU) stay, and a higher mortality risk. The systematic review and meta-analysis aimed to compare the efficacies between fiberoptic bronchoscopy (FOB) and general sputum suction for the prevention of VAP in patients with invasive MV.

Methodology: Relevant randomized controlled trials (RCTs) were obtained via a search of PubMed, Embase, Cochrane Library, Wanfang, and CNKI databases. A random-effects model was used to pool the results if significant heterogeneity was observed. Otherwise, a fixed-effects model was used.

Results: Sixteen RCTs were included. Compared to general sputum suction, sputum suction with FOB was associated with a significantly reduced risk of VAP (risk ratio [RR]: 0.56, 95% CI: 0.47 to 0.67, p < 0.001; $I^2 = 0\%$). Subgroup analyses showed that the combination of FOB-assisted sputum suction with bronchoalveolar lavage (BAL) further reduced the risk of VAP as compared to FOB-assisted sputum suction alone (p for subgroup difference = 0.04). In addition, FOB-assisted treatment was also associated with a reduced MV time (mean difference [MD]: -2.19 days, 95% CI: -2.69 to -1.68, p < 0.001; $I^2 = 18\%$), a shorter ICU stay (MD: 2.9 days, 95% CI: -3.68 to -2.13, p < 0.001; $I^2 = 34\%$), and a reduced mortality risk (RR: 0.46, 95% CI: 0.24 to 0.90, p = 0.02; $I^2 = 0\%$) in patients with invasive MV.

Conclusions: FOB for sputum suction and BAL in patients with invasive MV is effective in reducing the incidence of VAP.

Key words: Ventilator-associated pneumonia; fiberoptic bronchoscopy; sputum suction; bronchoalveolar lavage; meta-analysis.

J Infect Dev Ctries 2024; 18(9):1413-1420. doi:10.3855/jidc.17866

(Received 29 December 2022 – Accepted 28 March 2023)

Copyright © 2024 Tang et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Ventilator-associated pneumonia (VAP) is a hospital-acquired pneumonia that develops in patients receiving invasive mechanical ventilation (MV) for at least 48 hours [1,2]. According to previous studies, VAP is one of the most common nosocomial infections among patients who require MV, with a prevalence of 5 to 40% depending on the clinical settings and diagnostic criteria [2,3]. Clinically, the occurrence VAP poses a significant health risk for patients admitted to intensive care unit (ICU), causing increased mortality, longer hospital stays, and higher healthcare costs [1,3]. The risk factors of VAP include aging, multiple comorbidities, immunocompromised status, weakness of respiratory muscles, and male sex, etc. [3]. Pathophysiologically, endotracheal tubes interfere with the normal protective function of the upper airway, stimulate mucus production, and make the sputum clearance difficult, which become major mechanisms underlying the development of VAP [4,5]. Accordingly, intensive airway management is essential to prevent VAP in patients with MV [6]. Clinically, fiberoptic bronchoscopy (FOB) is a well-applied technique that could remove contamination and foreign materials from the airway and obtain pulmonary tissue samples for diagnosis [7]. Early use of FOB within 24 hours of intubation has been shown to improve the survival of patients with aspiration pneumonia [8]. In addition, the combination of FOB and bronchoalveolar lavage (BAL) can positively identify causative organisms in patients with aspiration-induced lung injury, and subsequently remove retained sputum from the airways of patients with obstinate pulmonary infection [9,10]. Interestingly, a recent clinical trial suggests that FOB may also be a useful treatment for VAP [11]. However, it remains unknown whether sputum suction assisted by FOB could reduce the risk of VAP as compared to general sputum suction in patients with invasive MV [12]. Accordingly, we performed a systematic review and meta-analysis of relevant randomized controlled trials (RCTs) to compare the efficacy of sputum suction assisted by FOB with general sputum suction for the prevention of VAP in these patients.

Methodology

This study adhered to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [13,14] and Cochrane Handbook [15] guidelines during its design and implementation.

Search strategy

To search Medline (PubMed), Embase (Ovid), CENTER (Cochrane Library), Wanfang, and CNKI (China National Knowledge Infrastructure) databases, the following strategies were used: (1) "bronchoscope" OR "bronchoscopic"; and (2) "ventilator-associated pneumonia" OR "VAP". Only studies including human subjects were considered. As a part of the final database search, references from related reviews and original articles were also screened. The final database search was carried out on September 28, 2022.

Study selection

The PICOS principle was followed in designating the inclusion criteria of the meta-analysis. P (patients): Patients with critical illnesses who were treated with invasive MV; I (intervention): A treatment group of FOB-assisted sputum suction with or without the combination of bronchoalveolar lavage (BAL); C (control): A control group of general sputum suction without the assistance of FOB; O (outcomes): The primary outcome was the incidence of VAP compared between patients of the FOB and the control groups. The secondary outcomes were the difference in MV time, ICU stay, and the risk of mortality between groups; S (study design): Parallel-group RCTs published as fulllength articles in English or Chinese.

Non-randomized studies, studies including patients with noninvasive MV, studies evaluating the role of FOB as a treatment of VAP, studies without using FOB, or studies that did not report the outcomes of interest were excluded. For studies with overlapped patient populations, the one with the largest sample size was selected for the meta-analysis.

Data collection and quality evaluation

Database searches, data collection, and quality assessment were carried out by two authors independently. Discussions with the corresponding author were conducted if disagreements occurred. We collected data on study information (first author, publication year, and study country), study design (blind or open-label), patient information (diagnosis, number of patients, mean age, and sex), details of FOBassisted treatment, details of controls, follow-up duration, diagnostic methods for VAP, and the outcomes. The Cochrane Risk of Bias Tool was used to determine the quality of the included RCTs [15] according to the following aspects: random sequence generation, allocation concealment, blinding of participants, blinding of outcome assessment, incomplete outcome data addressed, selective reporting, and other sources of bias.

Statistical analysis

Outcomes of discontinuous variables were summarized as risk ratio (RR) and corresponding 95% confidence interval (CI), while outcomes of continuous variables were presented as mean difference (MD) and 95% CI. Heterogeneity was assessed using the Cochrane Q test [15]. The I² statistic was also calculated, with $I^2 > 50\%$ indicating significant heterogeneity [16]. A random-effects model was used if significant between-study heterogeneity was observed; otherwise, a fixed-effects model was used [15]. Influencing analyses by excluding one study at a time from the meta-analysis were performed to evaluate the effect of each study on the pooled results [15]. Analysis of predefined subgroups was conducted to evaluate whether the result was consistent in studies with or without the combination of BAL, and in studies with clinically or microbiologically diagnosed VAP. An evaluation of publication bias was conducted via visual inspection of funnel plots and performing Egger's regression asymmetry test [17]. A p < 0.05 was considered as statistically significant. Statistical





analyses were conducted using the RevMan (Version 5.1; Cochrane, Oxford, UK) software.

Results

Literature search

The process of database searching and study identification is illustrated in Figure 1. Briefly, a database search yielded 796 articles, and 664 were retrieved after the duplicate records were excluded. Six hundred twenty-seven articles were subsequently excluded based on titles and abstracts, primarily because they were unrelated to the objective of the meta-analysis. Then, 21 out of the 37 articles that received full-text reviews were further excluded for the reasons illustrated in Figure 1. Finally, 16 RCTs [18-33] were considered to be eligible for the meta-analysis.

Study characteristics and data quality

An overview of the included studies can be found in Table 1. Overall, 16 RCTs involving 1,400 critically ill patients (mostly with respiratory failure) who were treated with invasive MV in the ICU were included in the meta-analysis [18-33]. All these studies were published between 2009 and 2021 and were performed in China. The mean ages of the patients varied between 39 and 75 years. The patients allocated to the intervention group received FOB-assisted sputum suction every 24 to 72 hours in all of the included studies, with [18,19,22,24,27,28,30-33] or without [20,21,23,25, 26,29] BAL. For patients allocated to the control group, general sputum suction without BAL was performed. The observational durations were within ICU stay or hospitalization. All of the included studies reported the outcome of VAP incidence, which [21,23,24,26,27,29-32] clinically were microbiologically [18-20,22,25,28,33] diagnosed. Using the Cochrane Risk of Bias Tool, Table 2 provides a detailed analysis of the included RCTs. All of the

Figure 2. Forest plots for the meta-analysis comparing FOBassisted sputum suction with general sputum suction on the incidence of VAP.

	FOE	3	Contr	ol		Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Fixed, 95% C	IV, Fixed, 95% CI		
He 2009	0	38	4	36	0.4%	0.11 [0.01, 1.89]			
Zhan 2010	5	20	11	19	4.4%	0.43 [0.18, 1.01]			
Zheng 2011	20	54	34	66	18.2%	0.72 [0.47, 1.09]	-		
Ma 2012	28	89	31	71	19.5%	0.72 [0.48, 1.08]	-		
Song 2012	2	54	12	52	1.5%	0.16 [0.04, 0.68]			
Aishan 2013	22	69	30	69	16.7%	0.73 [0.47, 1.14]	-		
Zhou 2014	8	60	24	60	6.2%	0.33 [0.16, 0.68]			
Zhang 2014	10	40	22	38	8.8%	0.43 [0.24, 0.79]	-		
Yue 2015	2	30	4	30	1.2%	0.50 [0.10, 2.53]			
Shu 2015	7	35	18	35	5.9%	0.39 [0.19, 0.81]			
Peng 2016	3	41	5	42	1.7%	0.61 [0.16, 2.41]			
Chen 2018	3	31	4	32	1.6%	0.77 [0.19, 3.18]			
Yan 2018	1	30	4	30	0.7%	0.25 [0.03, 2.11]			
Qiao 2018	2	38	4	35	1.2%	0.46 [0.09, 2.36]			
Wang 2019	9	39	19	39	7.4%	0.47 [0.25, 0.91]			
Cai 2021	7	43	11	35	4.6%	0.52 [0.22, 1.20]			
Total (95% CI)		711		689	100.0%	0.56 [0.47, 0.67]	•		
Total events	129		237				1		
Heterogeneity: Chi2 = 1	13.62, df =	: 15 (P	= 0.55); l ²	¹ = 0%					
Test for overall effect:	Z = 6.28 (P < 0.0	0001)				Eavoure EOR Eavoure control		

included studies were open-label. Details of random sequence generation were reported in seven studies [18,26,28-32], while none of them reported the details of allocation concealment. No evidence of selective reporting or other source of bias was detected.

Primary outcome

Overall, 16 studies [18-33] reported the influences of FOB-assisted sputum suction on the incidence of VAP. Results of the Cochrane Q test (p = 0.55) and I² statistic (0%) suggested a low between-group heterogeneity. Accordingly, results of the meta-analysis with a fixed-effects model showed that sputum suction with FOB was associated with a significantly low risk of VAP (RR: 0.56, 95% CI: 0.47 to 0.67, p < 0.001; Figure 2). Influencing analyses by excluding one study at a time showed consistent results (p < 0.05). Subgroup

Figure 3. Subgroup analyses comparing FOB-assisted sputum suction with general sputum suction on the incidence of VAP. A, subgroup analysis according to whether BAL was used; and B, subgroup analysis according to the diagnostic methods for VAP.

		FOB		Contr	ol		Risk Ratio	Risk Ratio
A.	Study or Subgroup	Events	Total	Events	Total	Weight	IV. Fixed, 95% C	IV. Fixed, 95% Cl
	1.2.1 WIT DAL	0	20		20	0.49/	0.44.10.04.4.001	
	He 2009	0	30	4	30	0.4%	0.11[0.01, 1.89]	_
	2010 Song 2012	2	20	12	52	4.470	0.43 [0.16, 1.01]	
	Zhang 2014	10	40	22	22	0.00/	0.10 [0.04, 0.00]	
	Zhang 2014	10	40	22	30	1 20/	0.43 [0.24, 0.79]	
	Fue 2015	2	30	4	42	1.276	0.50 [0.10, 2.55]	
	Van 2019	1	20	3	42	0.7%	0.01 [0.10, 2.41]	
	Oino 2018	2	30	4	35	1 294	0.25 [0.03, 2.11]	
	Wang 2019	<u></u>	30	10	30	7.4%	0.40 [0.03, 2.30]	-
	Cai 2021	7	43	11	35	4 6%	0.47 [0.23, 0.91]	
	Subtotal (95% CI)	'	373		356	31.9%	0.52 [0.22, 1.20]	•
	Total avanta	44	010	06	000	01.070	0.40 [0.01, 0.00]	•
	Heterogeneity: Chi2 = 3	52 df = 0	(P = 0	94)-12 =	0%			
	Test for overall effect: 7	r = 5.22 (P)	< 0.00	0001)	0 /0			
	restion overall encou. 2	0.ee (i	- 0.00	,001)				
	1.2.2 Without BAL							
	Zheng 2011	20	54	34	66	18.2%	0.72 [0.47, 1.09]	-
	Ma 2012	28	89	31	71	19.5%	0.72 [0.48, 1.08]	-
	Aishan 2013	22	69	30	69	16.7%	0.73 [0.47, 1.14]	-
	Zhou 2014	8	60	24	60	6.2%	0.33 [0.16, 0.68]	
	Shu 2015	7	35	18	35	5.9%	0.39 [0.19, 0.81]	
	Chen 2018	3	31	4	32	1.6%	0.77 [0.19, 3.18]	
	Subtotal (95% CI)		338		333	68.1%	0.64 [0.52, 0.79]	•
	Total events	88		141				
	Heterogeneity: Chi2 = 6	.02, df = 5	(P = 0)	.30); 12 =	17%			
	Test for overall effect: Z	= 4.04 (P	< 0.00	001)				
	T-1-1 (05% OI)				600	400.0%	0 50 10 47 0 671	•
	Total (95% CI)	100	/11	007	689	100.0%	0.56 [0.47, 0.67]	•
	Total events	129		237				
	Heterogeneity: Chi* = 1	3.62, df =	15 (P =	= 0.55); P	= 0%			0.005 0.1 1 10 200
	Test for overall effect: 2	= 6.28 (P	2 - 40	0001)	(D = 0	04) 12 - 7	E E0/	Favours FOB Favours control
	l est for subaroup differ	ences: Ch	11 ^e = 4.0	19. df = 1	(P = 0)	.04). 1* = 7	5.5%	
D		FOB		Contr	ol		Risk Ratio	Risk Ratio
—								
D	Study or Subgroup	Events	Total	Events	Total	Weight	IV, Fixed, 95% C	IV, Fixed, 95% Cl
	Study or Subgroup 1.3.1 Clinically diagno	Events	Total	Events	Total	Weight	IV. Fixed, 95% C	IV. Fixed. 95% CI
D _	Study or Subgroup 1.3.1 Clinically diagno Ma 2012	Events osed 28	Total 89	Events 31	Total 71	Weight 19.5%	IV, Fixed, 95% C	IV, Fixed, 95% Cl
D_	Study or Subgroup 1.3.1 Clinically diagno Ma 2012 Aishan 2013	Events osed 28 22	Total 89 69	Events 31 30	Total 71 69	Weight 19.5% 16.7%	IV, Fixed, 95% Cl 0.72 [0.48, 1.08] 0.73 [0.47, 1.14]	IV, Fixed, 95% Cl
D_	Study or Subgroup 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014	Events 28 22 10	70tal 89 69 40	31 30 22	Total 71 69 38	Weight 19.5% 16.7% 8.8%	IV. Fixed, 95% C 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79]	IV, Fixed, 95% Cl
D_	Study or Subgroup 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015	Events 28 22 10 2	89 69 40 30	31 30 22 4	Total 71 69 38 30	Weight 19.5% 16.7% 8.8% 1.2%	IV, Fixed, 95% C 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53]	IV. Fixed, 95% Cl
D _	Study or Subgroup 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015	Events 28 22 10 2 7	89 69 40 30 35	31 30 22 4 18	Total 71 69 38 30 35	Weight 19.5% 16.7% 8.8% 1.2% 5.9%	IV. Fixed, 95% C 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.19, 0.81]	IV. Fixed. 95% Cl
D_	Study or Subgroup 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015 Chen 2018	Events sed 28 22 10 2 7 3	89 69 40 30 35 31	31 30 22 4 18 4	71 69 38 30 35 32	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6%	IV. Fixed, 95% C 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.19, 0.81] 0.77 [0.19, 3.18]	IV. Fixed. 95% CI
D_	Study or Subgroup 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015 Chen 2018 Yan 2018	Events sed 28 22 10 2 7 3 1	89 69 40 30 35 31 30	Events 31 30 22 4 18 4 4	71 69 38 30 35 32 30	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7%	IV. Fixed, 95% C 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.19, 0.81] 0.77 [0.19, 3.18] 0.25 [0.03, 2.11]	I. IV. Fixed. 95% Cl
D _	Study or Subgroup 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015 Shu 2015 Chen 2018 Vian 2018 Qiao 2018	Events issed 28 22 10 2 7 3 1 2 2 7 3 1 2 2 2 2 2 2 2 2 2 2 2 2 2	Total 89 69 40 30 35 31 30 38	Events 31 30 22 4 18 4 4 4 4	Total 71 69 38 30 35 32 30 35 32	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.2%	V. Fixed, 95% Ci 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.19, 0.81] 0.77 [0.19, 3.18] 0.25 [0.03, 2.11] 0.46 [0.09, 2.36]	M. Fixed. 95% Cl
P_	Study or Subgroup 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015 Chen 2018 Yang 2018 Wang 2019	Events 10 28 22 10 2 7 3 1 2 9	Total 89 69 40 30 35 31 30 38 39	Events 31 30 22 4 18 4 19	Total 71 69 38 30 35 32 30 35 32 30 35 39	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.2% 7.4%	V. Fixed, 95% C 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.19, 0.81] 0.77 [0.19, 3.81] 0.25 [0.03, 2.11] 0.46 [0.09, 2.36] 0.47 [0.25, 0.91]	M. Fixed. 95% Cl
D _	Study or Subgroup 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015 Chen 2018 Yan 2018 Chan 2018 Wang 2019 Subtotal (95% Cl)	Events ssed 28 22 10 2 7 3 1 2 9	Total 89 69 40 30 35 31 30 38 39 401	Events 31 30 22 4 18 4 19	Total 71 69 38 30 35 32 30 35 39 379	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.2% 7.4% 63.0%	IV. Fixed, 95% Ci 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.19, 0.81] 0.77 [0.19, 3.18] 0.25 [0.03, 2.11] 0.46 [0.09, 2.36] 0.47 [0.25, 0.91] 0.59 [0.47, 0.74]	M, Fixed, 95% Cl
D_	Study or Subgroup 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015 Chen 2018 Yang 2018 Wang 2018 Subutotal (95% CI) Total events	Events ssed 28 22 10 2 7 3 1 2 9 84	Total 89 69 40 30 35 31 30 38 39 401	Events 31 30 22 4 18 4 4 4 4 19 136	Total 71 69 38 30 35 32 30 35 32 30 35 39 379	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.2% 7.4% 63.0%	IV. Fixed, 95% Ci 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.19, 0.81] 0.77 [0.19, 3.18] 0.25 [0.03, 2.11] 0.46 [0.09, 2.36] 0.47 [0.25, 0.91] 0.59 [0.47, 0.74]	N. Fixed. 95% Cl
D	Study or Subgroup 1.3.1 Clinically diagno Ma 2012 Linag 2014 Yue 2015 Shu 2015 Chen 2018 Yan 2018 Qiao 2018 Wang 2019 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = 5 Factor for the factor of	Events ased 28 22 10 2 7 3 1 2 9 84 47, df = 8 44 47, df = 8	Total 89 69 40 30 35 31 30 38 39 401 (P = 0	Events 31 30 22 4 18 4 19 1366	Total 71 69 38 30 35 32 30 35 39 379 0%	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.2% 7.4% 63.0%	IV. Fixed, 95% Cl 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.19, 0.81] 0.77 [0.19, 3.18] 0.77 [0.19, 3.18] 0.46 [0.09, 2.36] 0.47 [0.25, 0.91] 0.59 [0.47, 0.74]	M, Fixed, 95% Cl
D _	Study or Subgroup 1.3.1 Clinically diagnot Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015 Chan 2018 Qiao 2018 Subtotal (05% Cl) Total events Heterogeneity: Chi² = 5 Test for overall effect: Z	Events sed 28 22 10 2 7 3 1 2 9 84 47, df = 8 2 4.59 (P	Total 89 69 40 30 35 31 30 38 39 401 (P = 0) < 0.00	31 30 22 4 18 4 4 4 19 136 (.71); I ² = 0001)	Total 71 69 38 30 35 32 30 35 39 379 0%	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.2% 7.4% 63.0%	IV. Fixed, 95% CI 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.43] 0.39 [0.19, 0.81] 0.77 [0.19, 3.18] 0.25 [0.03, 2.11] 0.46 [0.09, 2.36] 0.47 [0.25, 0.91] 0.59 [0.47, 0.74]	M. Fixed. 95% Cl
D _	Study or Subgroup. 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2016 Chen 2018 Wang 2019 Subtotal (85% CI) Total events Heterogeneity: Chi² = 5 1.3.2 Microbiologicalija	Events seed 28 22 10 0 7 3 1 2 9 84 .47, df = 8 2 = 4.59 (P y confirmed)	Total 89 69 40 30 35 31 30 38 39 401 (P = 0 < 0.00 ed	31 30 22 4 18 4 4 4 19 136 (.71); I ² = 0001)	Total 71 69 38 30 35 32 30 35 39 379 0%	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.2% 7.4% 63.0%	IV. Fixed, 95% Cl 0.72 [0.48, 1.06] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.10, 2.53] 0.77 [0.19, 3.18] 0.25 [0.32, 2.11] 0.46 [0.09, 2.36] 0.47 [0.25, 0.91] 0.59 [0.47, 0.74]	M. Fixed. 95% Cl
D _	Study or Subgroup. 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015 Chen 2018 Wang 2018 Subtotal (95% CI) Total events Heterogeneity: Chi² = 5 Test for overall effect Z 1.3.2 Microbiologically He 2009	Events seed 28 22 10 10 2 7 3 1 2 9 84 2.47, df = 8 2 9 9 84 2 2.9 (P y confirmedout 0 0	Total 89 69 40 30 35 31 30 38 39 401 (P = 0 < 0.00 ed 38	31 30 22 4 18 4 4 4 19 136 .71); I ² = 0001)	Total 71 69 38 30 35 32 30 35 39 379 0%	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.2% 7.4% 63.0% 0.4%	IV. Fixed, 95% CJ 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.19, 0.81] 0.25 [0.3, 2.11] 0.46 [0.09, 2.36] 0.47 [0.25, 0.91] 0.59 [0.47, 0.74]	M, Fixed, 95% Cl
D _	Study or Subgroup. 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Aishan 2014 Yue 2015 Shu 2016 Chen 2018 Qiao 2018 Wang 2019 Subtotal (95% CI) Total events Heterogeneity: Chi* = 5 Tast for overall effect 2 1.3.2 Microbiologically He 2009 Zhan 2010	Events ssed 28 22 10 2 7 3 1 2 9 84 .47, df = 8 2 = 4.59 (P y 0 5	Total 89 69 40 30 35 31 30 38 39 401 (P = 0 < 0.00 ed 38 20	Events 31 30 22 4 18 4 19 136 0.71); I² = 0001) 4 11	Total 71 69 38 30 35 32 30 35 39 379 0% 36 19	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 63.0% 0.4% 4.4%	IV. Fixed, 95% CI 0.72 [0.48, 1.06] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.19, 0.81] 0.77 [0.19, 3.18] 0.25 [0.03, 2.11] 0.46 [0.09, 2.36] 0.47 [0.25, 0.91] 0.59 [0.47, 0.74] 0.11 [0.01, 1.89] 0.43 [0.18, 1.01]	M. Fixed. 95% Cl
D _	Study or Subgroup. 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015 Chen 2018 Wang 2019 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect: 2 1.3.2 Microbiologically He 2009 Zhang 2011	Events sed 28 22 10 2 7 3 1 2 9 84 47, df = 8 2 = 4.59 (P y confirme 0 5 20	89 69 40 30 35 31 30 35 31 30 35 31 30 38 39 401 (P = 0 0 ed 38 20 54	31 30 22 4 18 4 4 4 19 136 .71); I ² = 0001) 4 11 34	Total 71 69 38 30 35 32 30 35 39 379 0%	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.2% 7.4% 63.0% 0.4% 4.4% 18.2%	V. Fixed, 95% CI 0.72 [0.48, 1.06] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.77 [0.19, 3.18] 0.77 [0.19, 3.18] 0.47 [0.25, 0.91] 0.59 [0.47, 0.74] 0.47 [0.25, 0.91] 0.59 [0.47, 0.74] 0.41 [0.01, 1.89] 0.43 [0.18, 1.01]	
D _	Study or Subgroup. 1.3.1 Clinically diagno Ma 2012 Alshan 2013 Alshan 2014 Yue 2015 Shu 2016 Chen 2018 Qiao 2018 Wang 2019 Subtotal (95% CI) Total events Heterogeneity: Chi* = 5 1.3.2 Microbiologically He 2009 Zhan 2010 Zheng 2011 Song 2012	Events seed 28 22 10 2 7 3 1 2 9 84 4.47, df = 8 2 = 4.59 (P y confirme 0 5 20 2	89 69 40 30 35 31 30 35 31 30 35 31 30 38 39 401 (P = 0 < 0.00 ed 38 20 54 54 54	31 30 22 4 18 4 4 4 19 136 .71); I ² = 0001) 4 11 34 22	Total 71 69 38 30 35 32 30 379 0%	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.2% 63.0% 0.4% 4.4% 18.2% 1.5%	IV. Fixed, 95% CI 0.72 (0.48, 1.08) 0.73 (0.47, 1.14) 0.43 (0.24, 0.79) 0.59 (0.10, 2.53) 0.71 (0.10, 2.53) 0.71 (0.19, 3.18) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.26, 0.91) 0.47 (0.26, 0.91) 0.43 (0.18, 1.01) 0.72 (0.47, 1.08) 0.16 (0.04, 0.68)	M. Fixed. 95% Cl
	Study or Subgroup. 1.3.1 Glinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015 Chen 2018 Wang 2019 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Total events Heterogeneity: Chi ² = 5 Test for overall effect: 2 1.3.2 Microbiologically He 2009 Zhang 2011 Song 2012 Zhou 2014	Events sed 28 22 10 2 7 3 1 2 9 84 47, df = 8 2 = 4.59 (P y confirme 0 5 20 2 8	Total 89 69 40 30 35 31 30 38 39 401 (P = 0 0 0 0 20 54 60 54 60 60 0 0 10 <th1< th=""><th>31 30 22 4 18 4 4 4 19 136 (.71); I² = 0001) 4 11 34 12 24</th><th>Total 71 69 38 30 35 32 30 35 32 30 35 39 379 0%</th><th>Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.2% 7.4% 63.0% 0.4% 4.4% 18.2% 1.5% 6.2%</th><th>V. Fixed, 95% Cl 0.72 (0.48, 1.06) 0.73 (0.47, 1.14) 0.43 (0.24, 0.79) 0.50 (0.10, 2.53) 0.77 (0.19, 3.18) 0.77 (0.19, 3.18) 0.75 (0.03, 2.11) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.27, 0.94) 0.47 (0.17, 1.09) 0.42 (0.47, 1.09) 0.42 (0.47, 1.09) 0.43 (0.16, 0.68)</th><th></th></th1<>	31 30 22 4 18 4 4 4 19 136 (.71); I ² = 0001) 4 11 34 12 24	Total 71 69 38 30 35 32 30 35 32 30 35 39 379 0%	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.2% 7.4% 63.0% 0.4% 4.4% 18.2% 1.5% 6.2%	V. Fixed, 95% Cl 0.72 (0.48, 1.06) 0.73 (0.47, 1.14) 0.43 (0.24, 0.79) 0.50 (0.10, 2.53) 0.77 (0.19, 3.18) 0.77 (0.19, 3.18) 0.75 (0.03, 2.11) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.27, 0.94) 0.47 (0.17, 1.09) 0.42 (0.47, 1.09) 0.42 (0.47, 1.09) 0.43 (0.16, 0.68)	
	Study or Subgroup. 1.3.1 Clinically diagno Ma 2012 Alshan 2013 Alshan 2014 Yue 2015 Shu 2016 Chen 2018 Qiao 2018 Wang 2019 Subtotal (95% CI) Total events Heterogeneity: Ch ² = 5 1.3.2 Microbiologically He 2009 Zhan 2010 Zheng 2011 Song 2012 Zhou 2016	Events seed 28 22 10 2 7 3 1 2 7 3 1 2 9 84 4.7, df = 8 2 = 4.59 (P y confirme 0 5 20 2 8 3 3 1 2 3 3 3 1 2 3 3 3 2 4 5 9 2 2 3 3 2 3 3 3 2 2 3 3 3 3 3 3 2 3 3 3 2 3 3 3 3 3 3 3 3 3 3 3 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3	Second state 89 69 40 30 35 31 30 38 39 401 (P = 0, 0, 0) ed 38 20 54 54 54 60 41	Events 31 30 22 4 18 4 4 4 19 136 (.71); I ² = 0001) 4 11 34 12 24 5	Total 71 69 38 30 35 32 30 35 32 30 35 39 379 0%	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.2% 63.0% 63.0% 0.4% 4.4% 1.5% 6.2% 1.5%	IV. Fixed, 95% CI 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.10, 0.81] 0.77 [0.19, 3.18] 0.25 [0.03, 2.11] 0.46 [0.09, 2.36] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.24, 0.47] 0.43 [0.18, 1.01] 0.72 [0.47, 0.68] 0.43 [0.16, 0.68] 0.33 [0.16, 0.68] 0.31 [0.16, 2.41]	M. Fixed. 95% Cl
D _	Study or Subgroup. 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015 Chen 2018 Qiao 2018 Wang 2019 Subtotal (95% CI) Total events Heterogeneity: Chi² = 5 Test for overall effect: 2 1.3.2 Microbiologically He 2009 Zhang 2011 Song 2012 Zhou 2014 Peng 2016 Cai 2021	Events seed 288 22 10 2 2 7 3 1 2 9 84 47, df = 8 2 = 4.59 (P y confirmed 5 20 2 8 3 7 7 3 1 2 9 84 4.59 (P 84 5 9 9 84 5 9 84 5 9 9 8 8 7 7 7 7 8 8 2 8 8 7 7 7 8 8 8 7 8 8 7 7 8 8 7 7 9 9 9 8 7 7 7 8 8 7 7 7 8 8 7 8 8 7 7 8 8 8 7 7 9 9 8 8 7 7 8 8 7 8 8 7 7 8 8 7 8 8 7 7 8 8 7 7 9 8 8 7 7 7 7 8 8 7 7 7 7 7 7 8 8 7 7 7 8 7 7 7 7 7 8 7 7 7 7 7 7 7 7 7 7 7 7 7	Total 89 69 40 30 35 31 30 35 31 30 38 39 401 (P = 0 <<0.00 <<0.00 <<0.00 <<0.00 <<0.00 <<0.00 38 20 54 54 60 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <0.00 <th>31 30 22 4 18 4 4 4 19 136 .71); I² = 0001) 4 11 34 12 24 5 11</th> <th>Total 71 69 38 30 35 32 30 35 32 30 35 39 379 0%</th> <th>Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.6% 63.0% 0.4% 4.4% 18.2% 1.5% 6.2% 1.7% 4.6%</th> <th>IV. Fixed, 95% Cl 0.72 [0.48, 1.06] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.50 [0.10, 2.53] 0.77 [0.9, 3.18] 0.77 [0.47, 1.14] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.59 [0.47, 1.09] 0.33 [0.16, 0.68] 0.34 [0.16, 0.68] 0.45 [0.22, 1.20]</th> <th></th>	31 30 22 4 18 4 4 4 19 136 .71); I ² = 0001) 4 11 34 12 24 5 11	Total 71 69 38 30 35 32 30 35 32 30 35 39 379 0%	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.6% 63.0% 0.4% 4.4% 18.2% 1.5% 6.2% 1.7% 4.6%	IV. Fixed, 95% Cl 0.72 [0.48, 1.06] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.50 [0.10, 2.53] 0.77 [0.9, 3.18] 0.77 [0.47, 1.14] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.47 [0.26, 0.91] 0.59 [0.47, 1.09] 0.33 [0.16, 0.68] 0.34 [0.16, 0.68] 0.45 [0.22, 1.20]	
D _	Study or Subgroup. 1.3.1 Clinically diagno Ma 2012 Alshan 2013 Alshan 2014 Yue 2015 Shu 2016 Chen 2018 Qiao 2018 Wang 2019 Subtotal (95% CI) Total events Heterogeneity: Ch ² = 5 Tast for overall effect. 2 1.3.2 Microbiologically He 2009 Zhan 2010 Zhen 2011 Song 2012 Zhou 2014 Pong 2016 Cai 2021 Subtotal (95% CI)	Events seed 228 10 2 7 3 1 2 9 84 47, df = 8 2 = 4.59 (P y confirme 0 5 20 2 8 3 7 7	Total 89 69 40 30 35 31 30 38 39 401 (P = 0, 0.00 ed 38 20 54 60 41 43 310	Events 31 30 22 4 4 4 4 136 .71); I² = .0001) 4 11 34 .22 4 .11 34 .22 11 .34 12 .24 5 .11	Total 71 69 38 30 35 32 30 35 32 30 35 39 379 0% 0%	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 63.0% 0.4% 4.4% 18.2% 1.5% 6.2% 1.7% 4.6% 37.0%	IV. Fixed, 95% Cl 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.10, 0.81] 0.77 [0.19, 3.18] 0.25 [0.03, 2.11] 0.46 [0.09, 2.36] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.24, 0.47] 0.43 [0.18, 1.01] 0.72 [0.47, 0.74] 0.16 [0.04, 0.68] 0.33 [0.16, 0.68] 0.33 [0.16, 0.68] 0.35 [0.16, 2.41] 0.52 [0.22, 1.20]	M. Fixed 95% Cl
D _	Study or Subgroup. 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015 Chen 2018 Wang 2019 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = 5 Test for overall effect: 2 1.3.2 Microbiologically He 2009 Zhan 2010 Zhang 2011 Song 2012 Zhou 2014 Peng 2016 Cai 2021 Subtotal (95% Cl) Subtotal (95% Cl) Total events	Events seed 28 22 10 2 2 2 2 2 2 3 1 2 9 84 4-7, df = 8 2 = 4.59 (P y confirme 0 2 8 3 7 3 1 2 9 84 4-7, df = 8 2 2 8 3 7 3 1 2 9 84 4-7, df = 8 2 2 8 3 7 4-59 (P 9 8 4 4-59 (P 9 8 4 4-59 (P 9 8 4 4-59 (P 9 8 4 4-59 (P 9 8 4 4-59 (P 9 8 4 4-59 (P 9 8 4 4-59 (P 9 8 4 4-59 (P 9 8 4 4-59 (P 9 8 4 5 9 8 4 5 9 8 4 5 9 8 4 5 9 8 1 1 1 1 1 1 1 1 1 1 1 1 1	Total 89 69 30 30 35 31 30 38 39 401 (P = 0 0 0 0.000 ed 38 20 54 60 41 43 310	Events 31 30 22 4 18 4 4 4 19 136 (.71); I ² = 0001) 4 11 34 12 24 5 11 101	Total 71 69 38 30 35 32 30 35 39 379 0% 36 19 66 52 60 42 35 310	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 63.0% 0.7% 63.0%	V. Fixed, 95% Cl 0.72 (0.48, 1.06) 0.73 (0.47, 1.14) 0.43 (0.24, 0.79) 0.50 (0.10, 2.53) 0.50 (0.10, 2.53) 0.77 (0.19, 3.18) 0.77 (0.19, 3.18) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.11, 10, 11, 189) 0.43 (0.18, 10, 11) 0.43 (0.18, 10, 11) 0.43 (0.16, 0.68) 0.43 (0.16, 0.64) 0.45 (0.04, 0.68) 0.45 (0.04, 0.48) 0.45 (0.04, 0.48) 0.45 (0.04, 0.48) 0.45 (0.04, 0.48) 0.45 (0.04, 0.48) 0.	M. Fixed. 95% Cl
D _	Study or Subgroup. 1.3.1 Clinically diagno Ma 2012 Alshan 2013 Zhang 2014 Yue 2015 Shu 2016 Chan 2018 Qiao 2018 Wang 2019 Subtotal (95% CI) Total events Heterogeneity: Chi* = 5 Tast for oversitel effect: 2 1.3.2 Microbiologically He 2009 Zhan 2010 Zhen 2011 Song 2012 Zhou 2014 Peng 2011 Song 2012 Zhou 2016 Cai 2021 Subtotal (95% CI) Total events	Events 28 22 10 2 7 3 1 2 9 84 4.47, df = 8 2 4.59 (P y confirme 0 5 20 2 8 3 7 7 .20 .21 .21 .22 .22 .22 .22 .22 .23 .23 .24 .24 .24 .24 .24 .24 .24 .24	Total 89 69 40 30 35 31 30 30 38 39 401 (P = 0 0 cd 38 39 401 cd 40 30 30 30 30 30 30 30 30 30 3	311 300 222 4 4 18 4 4 4 4 19 1366 7.71); l ² = 1 300001) 4 4 11 134 4 22 4 5 11 101 11 101 1	Total 71 69 38 30 35 32 39 379 0% 36 19 66 52 65 20 60 42 35 310 22%	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 63.0% 0.7% 63.0%	IV. Fixed, 95% Cl 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.19, 0.81] 0.77 [0.19, 3.18] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.24, 0.47] 0.48 [0.04, 0.68] 0.43 [0.16, 0.68] 0.43 [0.16, 2.41] 0.52 [0.39, 0.70]	M. Fixed. 95% Cl
D _	Study or Subgroup. 1.3.1 Clinically diagno Mashan 2013 Alshan 2013 Zhang 2014 Yue 2015 Shu 2015 Chen 2018 Wang 2019 Subtotal (85% CI) Total events Heterogeneity: Chi* = 5 Test for overail effect: 2 Zhan 2010 Zhan 2010 Zhan 2011 Song 2012 Zhou 2014 You 2016 Cai 2021 Subtotal (95% CI) Total events Hear 2016 Cai 2021 Subtotal (95% CI) Total (95% CI) Total events Hear 2016 Cai 2021 Subtotal (95% CI) Total events Hear 2016 Cai 2021 Subtotal (95% CI) Total events Hear 2016 Cai 2021 Subtotal (95% CI) Total events Hear 2016 Cai 2021 Subtotal (95% CI	Events 28 28 22 10 2 7 3 1 2 9 84 4.47, df = 8 2 = 4.59 (P y confirme 0 5 20 2 8 3 7 7 5 20 2 9 8 4.59 (P 9 9 8 4.59 (P 9 9 8 4.59 (P 9 9 8 4.59 (P 9 9 8 4.59 (P 9 9 8 4.59 (P 9 9 8 8 4.59 (P 9 9 8 8 8 8 8 8 8 8 8 8 8 8 8	Total 89 89 69 40 30 30 35 31 30 30 38 39 401 402 200 402 38 20 54 54 54 54 54 54 310 412 433 310 $42 < 0.000$	311 300 222 4 4 4 19 136 137 171; 12 138 4 140 19 136 100001) 4 11 34 12 24 5 111 34 122 24 5 111 101 200; 12	Total 71 69 38 30 35 32 39 379 0% 36 19 66 52 60 42 35 310 22%	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 0.7% 1.2% 63.0% 0.4% 63.0%	IV. Fixed, 95% Cl 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.50 [0.10, 2.53] 0.71 [0.48, 1.08] 0.77 [0.48, 1.08] 0.77 [0.49, 3.18] 0.77 [0.49, 3.18] 0.77 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.43 [0.16, 1.01] 0.43 [0.16, 1.01] 0.43 [0.16, 0.61] 0.44 [0.16, 0.68] 0.61 [0.16, 2.41] 0.52 [0.22, 1.20] 0.52 [0.39, 0.70]	M. Fixed 95% Cl
D _	Study or Subgroup. 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015 Chan 2018 Wang 2019 Subtotal (95% CI) Total events Heterogeneity: Chi* = 5 Test for overall effect: 2 Ja.2 Microbiologically He 2009 Zhan 2010 Zheng 2011 Song 2012 Zhou 2014 Peng 2016 Cai 2021 Subtotal (95% CI) Total events Heterogeneity: Chi* = 7 Subtotal (95% CI) Total events Heterogeneity: Chi* = 7 Test for overall effect: 2 Subtotal (95% CI) Total events Heterogeneity: Chi* = 7 Test for overall effect: 2 Total (95% CI) Total (95% CI)	Events seed 28 22 10 2 7 3 1 2 9 84 4.7, df = 8 2 4.59 (P y confirme 0 2 8 3 7 2 2 7 3 1 2 9 84 4.7, df = 8 2 2 7 3 7 3 7 3 7 3 7 3 7 3 7 3 7 4.59 (P y confirme 2 2 7 3 7 3 7 3 7 3 7 3 7 3 7 3 7 3 7 7 3 7 7 3 7 7 3 7 7 7 7 7 7 7 7 7 7 7 7 7	Total 89 69 40 30 35 31 30 38 39 401 (P = 0 0) 6ed 20 54 54 60 141 43 310 (P = 0 0) < 0.000	Events 31 30 22 4 4 4 4 4 4 19 136 (71); P = (77); P	Total 71 69 38 30 35 52 30 35 379 0% 379 0% 36 52 60 0% 22% 889	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 1.6% 63.0% 0.4% 63.0% 0.4% 1.82% 1.5% 63.0% 1.2% 1.5% 63.0% 1.2% 1.2% 1.2% 1.2% 5.9% 5.9% 1.2% 5.9% 1.2% 5.9% 1.2% 1.5	IV. Fixed, 95% CI 0.72 (0.48, 1.06) 0.73 (0.47, 1.14) 0.43 (0.24, 0.79) 0.50 (0.10, 2.53) 0.50 (0.10, 2.53) 0.55 (0.03, 2.11) 0.43 (0.24, 0.79) 0.55 (0.03, 2.11) 0.46 (0.09, 2.36) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.26, 0.91) 0.47 (0.26, 0.91) 0.43 (0.14, 1.00) 0.43 (0.16, 16, 0.68) 0.93 (0.16, 0.68) 0.93 (0.16, 0.68) 0.92 (0.22, 1.20) 0.52 (0.23, 0.70) 0.52 (0.23, 0.70)	M. Fixed. 95% Cl
D _	Study or Subgroup. 1.3.1 Clinically diagno Ma 2012 Alshan 2013 Alshan 2014 Yue 2015 Shu 2016 Chen 2018 Qiao 2018 Wang 2019 Subtotal (95% CI) Total events Heterogeneity: Chi* = 5 Task for overall effect: 2 1.3.2 Microbiologically He 2009 Zhan 2010 Zhen 2010 Zhen 2010 Zhou 2014 Peng 2011 Soubtotal (95% CI) Total events Heterogeneity: Chi* = 7 Test for overail effect: 2 Total events Heterogeneity: Chi* = 7 Test for overail effect: 2	Events 28 28221002277 311229 84447, df = 8 28252102277 99844 447, df = 8 29997 844 447, df = 8 29977 200228 200257 200257 200257 200577 200577 200577 200577 2005777 2005777 20057777777777	$\begin{array}{c} \text{Total} \\ 89 \\ 69 \\ 40 \\ 30 \\ 35 \\ 31 \\ 30 \\ 38 \\ 39 \\ 401 \\ (P=0 \\ 0 < 0.00 \\ ed \\ 38 \\ 20 \\ ed \\ 41 \\ 43 \\ 310 \\ (P=0 \\ 43 \\ 310 \\ (P=0 \\ 0 < 0.00 \\ 711 \\ \end{array}$	Events 31 30 22 4 18 4 4 4 4 4 19 19 19 19 19 19 19 19 19 19	Total 71 9 38 30 35 32 30 35 39 379 0% 379 0% 36 19 66 52 60 42 35 310 22% 689	Weight 19.5% 16.7% 8.8% 1.2% 5.9% 0.7% 1.2% 63.0% 0.4% 4.4% 18.2% 1.2% 6.3.0% 0.4% 4.4% 18.2% 1.7% 6.3.0% 1.8% 0.7% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 6.3.0% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 6.3.0% 1.2% 1.2% 1.2% 6.3.0% 1.2% 1	IV. Fixed, 95% Cl 0.72 [0.48, 1.08] 0.73 [0.47, 1.14] 0.43 [0.24, 0.79] 0.50 [0.10, 2.53] 0.39 [0.10, 0.81] 0.77 [0.19, 3.18] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.25, 0.91] 0.47 [0.24, 0.47] 0.58 [0.47, 0.47] 0.52 [0.39, 0.70] 0.56 [0.47, 0.67]	M. Fixed 95% Cl
D _	Study or Subgroup. 1.3.1 Clinically diagno Ma 2012 Aishan 2013 Zhang 2014 Yue 2015 Shu 2015 Chan 2018 Wang 2019 Subtotal (95% CI) Total events Heterogeneity: Chi# = 5 Test for overail effect 2 Ja.2 Microbiologically He 2009 Zhan 2010 Zheng 2011 Song 2012 Zhou 2014 Peng 2016 Cai 2021 Subtotal (95% CI) Total events Heterogeneity: Chi# = 7 Test for overail effect: 2 Total events Heterogeneity: Chi# = 7 Total events Heterogeneity: Chi# = 7	Events - Events - 28 22 20 2 2 7 3 1 2 9 84 47, df = 8 84 47, df = 8 20 2 7 3 3 1 2 9 9 84 47, df = 8 20 2 7 7 3 3 1 2 9 9 9 84 47, df = 8 20 2 2 7 7 3 3 1 2 9 9 84 47, df = 8 20 2 2 7 7 3 3 1 2 9 9 84 47, df = 8 20 2 2 7 7 3 3 1 2 9 9 84 47, df = 8 20 2 2 7 7 3 3 1 2 2 9 9 84 47, df = 8 20 2 2 2 4.5 9 9 2 2 2 4.5 9 2 2 2 4.5 9 2 2 2 4.5 9 2 2 2 4.5 2 2 2 4.5 2 2 2 2 4.5 2 2 2 4.5 2 2 2 2 2 4.5 2 2 2 2 2 4.5 2 2 2 2 2 2 2 2 2 2 2 2 2	Total 89 69 9 40 30 35 31 30 35 31 30 35 31 30 36 60 401 60 60 60 60 41 43 310 60 60 411 43 310 $(P = 0 < 0.00)$ 7111 $15 (P = 2)$ 711 $15 (P = 2)$ 15 (Events 31 30 22 4 18 4 4 4 4 4 4 4 4 13 136 6 27 17 17 17 17 17 17 17 17 17 1	Total 71 69 38 30 35 32 30 379 0% 379 0% 36 19 66 52 60 42 35 310 22% 689	Weight 19.5% 16.7% 5.9% 1.2% 5.9% 7.4% 63.0% 0.4% 1.2% 7.4% 63.0% 1.2% 1.2% 7.4% 63.0% 1.2% 1.2% 1.4% 1.2% 7.4% 63.0% 1.2% 1.2% 1.4% 1.2% 7.4% 63.0% 1.2% 1.2% 1.2% 1.2% 1.4% 1.2% 1.2% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2	IV. Fixed, 95% CI 0.72 (0.48, 1.08) 0.73 (0.47, 1.14) 0.43 (0.24, 0.79) 0.50 (0.10, 2.53) 0.50 (0.10, 2.53) 0.55 (0.03, 2.11) 0.46 (0.09, 2.36) 0.47 (0.154) 0.47 (0.154) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.26, 0.91) 0.47 (0.26, 0.91) 0.59 (0.47, 1.09) 0.33 (0.16, 0.68) 0.93 (0.16, 0.68) 0.93 (0.16, 0.68) 0.92 (0.22, 1.21) 0.52 (0.22, 1.22) 0.52 (0.22, 1.22) 0.52 (0.23, 0.70) 0.56 [0.47, 0.67]	M. Fixed. 95% Cl
D_	Study or Subgroup. 1.3.1 Clinically diagon Ma 2012 Alshan 2013 Zhang 2014 Yue 2015 Shu 2016 Chan 2018 Qiao 2018 Wang 2019 Subtotal (95% CI) Total events Heterogeneity: Chi* = 5 Tast for overall effect: 2 1.3.2 Microbiologically He 2009 Zhan 2010 Zhan 2010 Zhan 2010 Zhan 2010 Zhan 2010 Zhan 2010 Heterogeneity: Chi* = 1 Heterogeneity: Chi* = 7 Test for overall effect: 2 Total events Heterogeneity: Chi* = 1 Test for vorrall effect: 2	Events 28 22 22 22 2 2 7 3 1 2 9 9 4.47, df = 8 4.59 (P (C) 2 2 3 1 2 9 9 9 9 9 9 9 9 9 9 9 9 9	Total 89 69 40 300 35 31 30 38 39 401 (P = 0.00 ed 38 20 54 54 60 41 43 310 (P = 0.000) (P = 0.000) < 0.000)	Events 31 30 22 4 4 4 4 136 6 0,711; P = 136 1300001) 4 11 134 122 24 4 4 122 11 101 122 122 24 5 11 101 101 237; P = 0.555; P = 0.0501	Total 71 69 38 30 35 32 30 379 0% 379 0% 36 19 66 52 66 52 310 22% 689 22%	Weight 19.5% 16.7% 8.8% 1.2% 1.2% 1.2% 1.2% 1.5% 6.3.0% 0.4% 4.4% 18.2% 4.6% 37.0% 100.0%	IV. Fixed, 95% Cl 0.72 (0.48, 1.08) 0.73 (0.47, 1.14) 0.43 (0.24, 0.79) 0.50 (0.10, 2.53) 0.39 (0.110, 0.81) 0.77 (0.19, 3.18) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.25, 0.91) 0.47 (0.27, 0.74) 0.41 (0.04, 0.68) 0.33 (0.16, 0.68) 0.33 (0.16, 0.68) 0.33 (0.16, 2.41) 0.52 (0.22, 1.20) 0.52 [0.39, 0.70] 0.56 [0.47, 0.67]	M. Fixed 95% Cl

analyses showed that the combination of FOB-assisted sputum suction with BAL was associated with a further reduced risk of VAP (RR: 0.43, 95% CI: 0.31 to 0.59, p < 0.001) as compared to FOB-assisted sputum suction alone (RR: 0.64, 95% CI: 0.52 to 0.79, p < 0.001; p for subgroup difference = 0.04; Figure 3A). In addition, consistent results were observed in studies with clinically diagnosed VAP (RR: 0.59, 95% CI: 0.47 to 0.74, p < 0.001) and microbiologically confirmed VAP (RR: 0.52, 95% CI: 0.39 to 0.70, p < 0.001; p for subgroup difference = 0.52; Figure 3B). No severe adverse events were reported that were deemed to be relevant to the FOB-assisted treatment.

Table 1. Study characteristics.

Secondary outcomes

Pooled results with 11 studies [18,20-23,25-30] using a fixed-effects model showed that sputum suction with FOB was also associated with a reduced time of MV (MD: -2.19 days, 95% CI: -2.69 to -1.68, p < 0.001; $I^2 = 18\%$; Figure 4A). Besides, meta-analyses of six studies [18, 20-23, 28] indicated that FOB-assisted sputum suction was also associated with a shorter ICU stay (MD: 2.90 days, 95% CI: 3.68 to 2.13, p < 0.001; $I^2 = 34\%$; Figure 4B). Finally, pooled results from four studies [18,25,29,30] suggested that FOB-assisted sputum suction was also associated with a reduced mortality risk during ICU stay or hospitalization (RR:

Study	Country	Design	Diagnosis	Setting	Patient number	Mean age	Male	Intervention	Control	Follow-up duration	Diagnosis of VAP	Outcomes reported
He 2009	China	RCT, OL	AECOPD and RF	RICU	74	67.1	85.1	BSS and BAL every 24-72 hours	RSS	Within RICU stay	Microbiologically confirmed	VAP, mortality, MV time and ICU stay
Zhan 2010	China	RCT, OL	RF patients with respiratory muscle weakness	ICU	39	46.1	61.5	BSS and BAL every 24-72 hours	RSS	Within ICU stay	Microbiologically confirmed	VAP
Zheng 2011	China	RCT, OL	RF	ICU	120	NR	80	BSS every 24 hours	RSS	Within hospitalization	Microbiologically confirmed	VAP, MV time and ICU stay
Ma 2012	China	RCT, OL	Older people with RF	ICU	160	74.5	58.1	BSS every 48 hours	RSS	Within ICU stay	Clinically diagnosed	VAP, MV time and ICU stay
Song 2012	China	RCT, OL	AECOPD and RF	RICU	106	67.9	76.4	BSS and BAL every 24-48 hours	RSS	Within RICU stay	Microbiologically confirmed	VAP, MV time and ICU stay
Aishan 2013	China	RCT, OL	Older people with RF	ICU	138	NR	NR	BSS every 48 hours	RSS	Within hospitalization	Clinically diagnosed	VAP, MV time and ICU stay
Zhou 2014	China	RCT, OL	Critically ill patients	ICU	120	47	85	BSS every 24 hours	RSS	Within hospitalization	Microbiologically confirmed	VAP, mortality, and MV time
Zhang 2014	China	RCT, OL	RF patients with respiratory muscle	ICU	78	51	61.5	BSS and BAL every 24-72 hours	RSS	Within ICU stay	Clinically diagnosed	VAP
Yue 2015	China	RCT, OL	weakness AECOPD and RF	ICU	60	67.2	53.3	BSS and BAL every 24-72 hours	RSS	Within hospitalization	Clinically diagnosed	VAP, and MV time
Shu 2015	China	RCT, OL	Patients with RF	ICU	70	60.3	55.7	BSS every 72 hours	RSS	Within hospitalization	Clinically diagnosed	VAP, and MV time
Peng 2016	China	RCT, OL	Patients with RF	ICU	83	65.3	72.3	BSS and BAL every 48-72 hours	RSS	Within hospitalization	Microbiologically confirmed	VAP, MV time and ICU stay
Chen 2018	China	RCT, OL	Patients with ARDS	ICU	63	54.9	54	BSS every 24 hours	RSS	Within hospitalization	Clinically diagnosed	VAP, mortality, and MV time
Yan 2018	China	RCT, OL	RF patients with respiratory muscle weakness	ICU	60	58.4	68.3	BSS and BAL every 24-72 hours	RSS	Within hospitalization	Clinically diagnosed	VAP
Qiao 2018	China	RCT, OL	AECOPD and RF	ICU	73	64.8	58.5	BSS and BAL every 24-72 hours	RSS	Within hospitalization	Clinically diagnosed	VAP, mortality, and MV time
Wang 2019	China	RCT, OL	RF patients with respiratory muscle weakness	ICU	78	53.8	55.1	BSS and BAL every 24-72 hours	RSS	Within hospitalization	Clinically diagnosed	VAP
Cai 2021	China	RCT, OL	Coma patients on MV	EICU	78	39.4	70.5	BSS and BAL every 24-72 hours	RSS	Within hospitalization	Microbiologically confirmed	VAP

VAP, ventilator-associated pneumonia; ICU, intensive care unit; RICU, respiratory ICU; EICU, emergency ICU; RCT, randomized controlled trial; OL, open-label; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; RF, respiratory failure; ARDS, acute respiratory distress syndrome; MV, mechanical ventilation; BAL, bronchoalveolar lavage. BSS, Bronchoscopic sputum suction; RSS, Routine sputum suction when necessary.

Table 2. Quality evaluation by the Cochrane Risk of Bias Tool.

Study	Random sequence	Allocation	Blinding of	Blinding of outcome	Incomplete	Selective	Other sources of
	generation	concealment	participants	assessment	outcome data	reporting	bias
					addressed		
He 2009	Low risk	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Zhan 2010	Unclear	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Zheng 2011	Unclear	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Ma 2012	Unclear	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Song 2012	Unclear	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Aishan 2013	Unclear	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Zhou 2014	Unclear	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Zhang 2014	Unclear	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Yue 2015	Unclear	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Shu 2015	Low risk	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Peng 2016	Low risk	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Chen 2018	Low risk	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Yan 2018	Low risk	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Qiao 2018	Low risk	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Wang 2019	Low risk	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Cai 2021	Unclear	Unclear	High risk	High risk	Low risk	Low risk	Low risk

0.46, 95% CI: 0.24 to 0.90, p = 0.02; $I^2 = 0$ %; Figure 4C).

Publication bias

The funnel plots for the meta-analyses comparing FOB-assisted treatment with controls on the risk of VAP and the duration of ICU stay are shown in Figures 5A and 5B. The plots were symmetrical on vision inspection, suggesting low risks of publication biases. Egger's regression tests also suggested low risks of publication biases (p = 0.15 and 0.29, respectively).

Discussion

In this meta-analysis, we pooled the results of 16 RCTs, and the results showed that compared to general

Figure 4. Forest plots for the meta-analysis comparing FOBassisted sputum suction with general sputum suction on the time of MV, ICU stay, and mortality. A, forest plots for the outcome of MV duration; B, forest plots for the outcome of ICU stay, and C, forest plots for the outcome of mortality.



sputum suction, FOB-assisted sputum suction could significantly reduce the incidence of VAP in patients who were treated with invasive MV. Moreover, subgroup analyses showed that FOB-assisted sputum suction combined with BAL could further reduce the risk of VAP as compared to FOB-assisted sputum suction alone. In addition, the preventative efficacy of FOB-assisted sputum suction on VAP was consistent in studies with clinically diagnosed VAP and

Figure 5. Funnel plots for the meta-analysis evaluating the publication biases of the meta-analyses. A, funnel plots for the outcome of VAP risk; and B, funnel plots for the outcome of mortality.



microbiologically confirmed VAP. Finally, subsequent meta-analyses showed that FOB-assisted sputum suction was also associated with a reduced MV time, a shortened ICU stay, and a decreased mortality in patients who were treated with invasive MV. Collectively, these findings indicate that the use of FOB assisted sputum suction and BAL could reduce the incidence of VAP in patients with invasive MV.

To the best of our knowledge, this may be the first meta-analysis that systematically evaluated the role of FOB-assisted sputum suction in patients who were treated with invasive MV. The methodological strengths of the meta-analysis include the following. First, an extensive literature search was performed in five electronic databases, which retrieved the most up-todate RCTs according to the aim of the meta-analysis. Second, for the primary outcome of VAP, we performed multiple sensitivity and subgroup analyses, and the consistent results of these analyses further confirmed the robustness of the findings. Finally, besides investigating the influence of FOB-assisted sputum suction on VAP, we also explored the effects of FOB on other clinical outcomes that have been confirmed to be related to VAP. The benefits of FOB on these secondary outcomes such as MV time, ICU stay, and mortality may be directly related to the preventative efficacy of FOB-assisted sputum suction on VAP incidence.

An early retrospective study showed that although diagnostic FOB was associated with shorter hospital stays and duration of antibiotics in patients with VAP, a therapeutic FOB failed to show a benefit on clinical outcomes in these patients [34]. However, as acknowledged by the authors of the study, no definition conclusion could be made regarding the role of therapeutic FOB for VAP because of the limitations of a retrospective design. A recent RCT showed that using FOB-assisted sputum suction every other day could more effectively control the fever symptoms, reduce the leukocyte count, and lower APACHE II scores in patients with VAP as compared to the group of general sputum suction [11], suggesting a potential benefit of therapeutic FOB in patients with VAP. Since optimized airway management is a key process to prevent VAP in patients with invasive MV, some small-scale RCTs have been performed to evaluate the potential role of FOB in the prevention of VAP. Given the limited sample sizes of these studies, a meta-analysis was performed in this study for a comprehensive evaluation. Results of the current meta-analysis support that FOB-assisted sputum suction is effective in reducing the risk of VAP as compared to general sputum suction. These results were consistent with the previously observed benefits

of therapeutic FOB in patients with aspiration pneumonia [8] and refractory pneumonia [35]. These findings indicate that therapeutic FOB is especially beneficial for patients with aspiration pneumonia [36]. Interestingly, our subgroup analysis showed that FOBassisted sputum suction combined with BAL could further reduce the risk of VAP compared to FOBassisted sputum suction alone. As shown in previous studies, a diagnostic BAL is more effective to provide the microbiological diagnosis of pneumonia and thereby guide the adjustment of the antibiotics [37]. In addition, therapeutic BAL may also be helpful in removing retained sputum from the airways of patients with obstinate pulmonary infection, such as patients who were treated with MV in the ICU [9]. Collectively, these findings suggest that FOB sputum suction combined with BAL should be applied to prevent VAP in high-risk patients who were treated with MV.

Our meta-analysis has several limitations. First, all the included studies were from China. Studies should be performed in other countries for validation. Moreover, all the included studies were open-label. However, blinded studies are difficult to conduct in this clinical scenario by using FOB. In addition, a pulmonary infection control (PIC) window is an important parameter that is used to reflect control of the infection at which time patients undergo extubation and transition to non-invasive ventilation. By influencing the timing of extubation, PIC may confound the duration of MV and the incidence of VAP. However, only one of the included studies [30] confirmed that patients from both groups were treated with sequential invasive-noninvasive mechanical ventilation at the PIC window. The imbalance of PIC between groups may affect the findings of the studies. Furthermore, the experience of physicians who performed the FOBassisted sputum suction and BAL may affect the results of the meta-analysis, which should be evaluated in future studies. Besides, an optimal protocol and frequency of therapeutic FOB in high-risk patients for VAP remains to be determined. Additionally, only studies published as full-length articles in peerreviewed journals were included, and we did not include grey literature such as conference abstracts or unpublished data because these literatures are not likely to be peer-reviewed. Grey literature may have less reliable results, and including these data in the metaanalysis may compromise the validity of the findings. We acknowledged that excluding this literature may lead to publication bias. However, funnel plots and Egger's regression tests in this meta-analysis did not suggest a significant risk of publication bias. Finally, limited studies were included in the meta-analysis regarding the influence of FOB on the mortality of patients receiving invasive MV. These findings should be validated in large-scale RCTs.

Conclusions

In conclusion, the results of the meta-analysis indicate that the use of FOB for sputum suction could reduce the risk of VAP in patients with invasive MV, and the preventative efficacy of FOB for VAP could be reinforced if BAL is combined with FOB. These findings suggest that BAL-assist sputum suction is effective in preventing VAP and improving the clinical outcomes in high-risk patients who are treated with invasive MV.

Authors' contributions

Haowei Tang and Zhi Yuan conceived the study. Haowei Tang and Jingjie Li performed literature review and data collection. Haowei Tang, Qun Wang, and Weijie Fan performed data statistics and interpreted the results. Haowei Tang drafted the manuscript. All authors approved the submission of the manuscript.

References

- Frondelius T, Atkova I, Miettunen J, Rello J, Jansson MM (2022) Diagnostic and prognostic prediction models in ventilator-associated pneumonia: systematic review and metaanalysis of prediction modelling studies. J Crit Care 67: 44-56. doi: 10.1016/j.ejim.2023.11.009.
- Weinberger J, Cocoros N, Klompas M (2021) Ventilatorassociated events: epidemiology, risk factors, and prevention. Infect Dis Clin North Am 35: 871-899. doi: 10.1016/j.idc.2021.07.005.
- 3. Li Y, Liu C, Xiao W, Song T, Wang S (2020) Incidence, risk factors, and outcomes of ventilator-associated pneumonia in traumatic brain injury: a meta-analysis. Neurocrit Care 32: 272-285. doi: 10.1007/s12028-019-00773-w.
- Kallet RH (2019) Ventilator bundles in transition: from prevention of ventilator-associated pneumonia to prevention of ventilator-associated events. Respir Care 64: 994-1006. doi: 10.4187/respcare.06966.
- Augustyn B (2007) Ventilator-associated pneumonia: risk factors and prevention. Crit Care Nurse 27: 32-36, 38-39. doi: 10.4037/ccn2007.27.4.32.
- Modi AR, Kovacs CS (2020) Hospital-acquired and ventilatorassociated pneumonia: diagnosis, management, and prevention. Cleve Clin J Med 87: 633-639. doi: 10.3949/ccjm.87a.19117.
- Scala R, Guidelli L (2021) Clinical value of bronchoscopy in acute respiratory failure. Diagnostics (Basel) 11: 1755. doi: 10.3390/diagnostics11101755.
- Lee HW, Min J, Park J, Lee YJ, Kim SJ, Park JS (2015) Clinical impact of early bronchoscopy in mechanically ventilated patients with aspiration pneumonia. Respirology 20: 1115-1122. doi: 10.1111/resp.12590.

- Fagon JY (2006) Diagnosis and treatment of ventilatorassociated pneumonia: fiberoptic bronchoscopy with bronchoalveolar lavage is essential. Semin Respir Crit Care Med 27: 34-44. doi: 10.1055/s-2006-933672.
- Wang C, Ye S, Wang X, Zhao Y, Ma Q, Wang L (2019) Clinical efficacy and safety of mechanical ventilation combined with fiberoptic bronchoalveolar lavage in patients with severe pulmonary infection. Med Sci Monit 25: 5401-5407. doi: 10.12659/MSM.915507.
- 11. Karbasy SH, Sabertanha A, Bayati M, Meshkini A, Fatemeh Shakhs Emampour B (2021) Study of the effect of added bronchoscopic suction to routine treatment of ventilator associated pneumonia patients in surgical ICU. J Pak Med Assoc 71: 1326-1331.
- Nannapaneni S, Silvis J, Curfman K, Chung T, Simunich T, Morrissey S (2022) Bronchoscopy decreases ventilatorassociated pneumonia in trauma patients. Am Surg 88: 653-657. doi: 10.1177/00031348211058639.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372: n71. doi: 10.1136/bmj.n71.
- Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372: n160. doi: 10.1136/bmj.n160.
- Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M (2021) Cochrane handbook for systematic reviews of interventions version 6.2. The Cochrane Collaboration.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. doi: 10.1136/bmj.327.7414.557.
- Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. doi: 10.1136/bmj.315.7109.629.
- He SP, Wang XP, Li DM, He WY, Wu JF, Li QL (2009) Weaning from mechanical ventilation by sequential invasive to noninvasive ventilation assisted with fiberoptic bronchoscopy in patients with COPD. Chin J Pract Med 36: 4-6. [Article in Chinese]
- Zhan YA, Qian KJ, Wang LQ, Zeng ZG, Liu F, Zhu F (2010) Effect of bronchofibroscope in the prevention and treatment for ventilator associated pneumonia in ICU patients combined with respiratory muscle weakness. Jiangxi Med J 46: 1-3. [Article in Chinese]
- Zheng HY, Zheng HY, FL P, Liu HJ, FC L (2011) Observation on the effect of sputum aspiration with fiberoptic bronchoscope in preventing ventilator-associated pneumonia. Shandong Med 51: 21. [Article in Chinese]
- Ma XB, Li SQ, Chen YJ, Gao L (2012) Application of fiberoptic bronchoscope in the prevention of elderly patients with ventilator-associated pneumonia. Chin J Gerontol 32: 4989-4990. [Article in Chinese]
- Song RR, Qiu YP, Chen YJ, Ji Y (2012) Application of fiberoptic bronchscopy in patients with acute exacerbations of chronic obstructive pulmonary disease during sequential weaning of invasive-noninvasive mechanical ventilation. World J Emerg Med 3: 29-34. doi: 10.5847/wjem.j.issn.1920-8642.2012.01.005.
- Aishan G (2013) Role of fiberoptic bronchoscope in the prevention of elderly patients with ventilator-associated pneumonia. Med Inform 26: 193.

- 24. Zhang X (2014) Effect of bronchofibroscope in the prevention and treatment for ventilator associated pneumonia in ICU patients combined with respiratory muscle weakness. Chin Health Indust 23: 100-102. [Article in Chinese]
- Zhou ZY, Xie XH, Tian J (2014) Effect of upper respiratory tract management with fiberoptic bronchoscope on preventing ventilator-associated pneumonia. Guangdong Med 35: 3702-3704. [Article in Chinese]
- Shu DD (2015) Application of fiberoptic bronchoscopy and conventional sputum suction therapy on prevention of ventilator associated pneumonia. Clin Pulm Med 20: 698-701.
- 27. Yue Y (2015) The influence of effect and complication of bronchoscopy on the mechanical ventilation in the treatment of COPD patients with respiratory failure. Chin J Crit Care Med 35: 355-358. [Article in Chinese]
- Peng ZY, Long GL, Bai LY, Chen XR, Xiong GY (2016) Influence of comprehensive intervention measures on incidence of ventilator-associated pneumonia in coma patients. Chin J Nosocomiol 26: 4638-4640. [Article in Chinese]
- 29. Chen Y, Chen G (2018) Application of fiberoptic bronchoscopy in mechanical ventilation of patients with acute respirotary distress syndrome. Chin J Prim Med Pharm 25: 306-309. [Article in Chinese]
- Qiao Z, Yu J, Yu K, Zhang M (2018) The benefit of daily sputum suction via bronchoscopy in patients of chronic obstructive pulmonary disease with ventilators: A randomized controlled trial. Medicine (Baltimore) 97: e11631. doi: 10.1097/MD.000000000011631.
- Yan CR (2018) Prevention and treatment of ventilatorassociated pneumonia in ICU patients with respiratory muscle weakness by fiberoptic bronchoscopy. Clin Pract 22: 1027-1028. [Article in Chinese]
- 32. Wang XY (2019) Analysis of the Preventive and therapeutic effects of fiberoptic bronchoscopy on ventilator-associated pneumonia in patients with ICU respiratory muscle weakness.

Clin Med Dev Inform 12: 89-90. doi: 10.1007/s10238-011-0143-8.

- Cai TT, Li TX, Xue QP (2021) Clinical study on prevention and treatment of early-onset ventilator-associated pneumonia with fiberoptic bronchoscopy. Jilin Med 42: 1613-1615. [Article in Chinese]
- 34. Guidry CA, Mallicote MU, Petroze RT, Hranjec T, Rosenberger LH, Davies SW (2014) Influence of bronchoscopy on the diagnosis of and outcomes from ventilator-associated pneumonia. Surg Infect (Larchmt) 15: 527-532. doi: 10.1089/sur.2013.142.
- Fang Z, Lin S, Luo S, Xu L, Zhang H, Pei Y (2021) Metaanalysis and systematic review of electronic bronchoscopy in refractory pneumonia. Ann Palliat Med 10: 9889-9901. doi: 10.21037/apm-21-2133.
- Raghavendran K, Nemzek J, Napolitano LM, Knight PR (2011) Aspiration-induced lung injury. Crit Care Med 39: 818-826. doi: 10.1097/CCM.0b013e31820a856b.
- 37. Pereira Gomes JC, Pedreira WL, Jr., Araujo EM, Soriano FG, Negri EM, Antonangelo L (2000) Impact of BAL in the management of pneumonia with treatment failure: positivity of BAL culture under antibiotic therapy. Chest 118: 1739-1746. doi: 10.1378/chest.118.6.1739.

Corresponding author

Dr. Zhi Yuan, Department of Respiratory Medicine, Fenghua District People's Hospital, 36 Gongyuan Road, Ningbo 315500, China Telephone: 86-574-88587000 Fax: 86-574-88587000

Email: zhiyuan_9328@21cn.com

Conflict of interests: No conflict of interests is declared.